Table 2.

Real-world studies conducted in Asia comparing afatinib with first-generation EGFR TKIs or other relevant treatments in EGFR mutation-positive NSCLC: summary of results for subgroups with uncommon EGFR mutations and brain metastases at baseline

Study	Treatment	Patients (n)	Clinical outcome (months)	p valuea
Subgroup with uncommon EGFR mutationsb
South Korea
Kim et al. [30]	Afatinib	14	PFS: not reached	0.06
	Gefitinib	12	PFS: 5.0
	Erlotinib	5	PFS: 6.1
Taiwan
Lin et al. [32]	Afatinib	17	OS: 38.6	0.81
	Gefitinib	10	OS: not reached
	Erlotinib	4	OS: 33.6
Shen et al. [44]	Afatinib	24	PFS: 11.0c	0.03
	Gefitinib	32 (combined)	PFS: 3.6 (combined)
	Erlotinib
Tu et al. [34]	Afatinib	23	PFS: 19.7	0.506
	Gefitinib	14	PFS: 7.0
	Erlotinib	12	PFS: 7.0
Yang et al. [74]	Afatinib	17	PFS: 5.5	0.3025
	Gefitinib	31	PFS: 6.2
	Erlotinib	9	PFS: 9.0
Subgroup with brain metastases at baseline
South Korea
Kim et al.d [30]	Afatinib only	71 (combined)	PFS: 15.7	0.21
	Afatinib + WBRT		PFS: 11.5
	Afatinib + GKS		PFS: 15.6
Taiwan
Kuan et al. [31]	Afatinib	17	PFS	HR: 0.42 (95% CI 0.16–1.05)e
	Gefitinib	60
	Erlotinib	11
Su et al. [54]	Afatinib	NRf	PFS: 8.2	0.34
	Gefitinib		PFS: 10.5
	Erlotinib		PFS: 10.4
Tu et al. [34]	Afatinib	22	PFS: 9.9	0.367
	Gefitinib	34	PFS: 8.9
	Erlotinib	17	PFS: 7.2

CI confidence interval, EGFR epidermal growth factor receptor, GKS gamma knife surgery, HR hazard ratio, NR not reported, NSCLC non-small cell lung cancer, OS overall survival, PFS progression-free survival, TKIs tyrosine kinase inhibitors, WBRT whole brain radiotherapy

^aAfatinib versus comparator(s)

^bEGFR mutations other than Del19 or L858R

^cExcluded patients with EGFR exon 20 insertions

^dData for gefitinib and erlotinib not reported

^eHR for afatinib versus gefitinib

^fOverall, 115, 116, and 75 patients received afatinib, gefitinib, and erlotinib, respectively; however, the number of patients with brain metastases at baseline was not reported